Tag Archives: finance

Roche Reports Good Half-Year Performance

Roche reports a rise in sales to 22,974 million Swiss francs (+5%, US$25.5 billion) for the first half of 2014, with strong growth from HER2 breast cancer medicines, Herceptin, Perjeta and Kadcyla, and other oncology medicines, Avastin and MabThera/Rituxan. Sales of Xeloda, a chemotherapy drug which is no longer patent-protected, were lower, as a result […]
Posted in Europe, Guest Blog | Also tagged | Leave a comment

Pharm Exec's 2014 Dealmakers Outlook

After fading to dreary summer stock for the past few years, dealmaking is today back to center stage, but with the major roles reversed— small biotech, yesterday’s understudy, now gets top billing, while big Pharma has to work harder for its close-up. Pharm Exec brought partner Campbell Alliance and a select group of West Coast […]
Posted in Deals, Global, Strategy | Also tagged , , | Leave a comment

Rise in IPOs Eases Pharma's Investment Woes

Private equity and venture capital (PEVC) deal activity decreased from 1063 in 2010 to 480 in 2013, according to a new Frost & Sullivan report. And the pharma, biotech and healthcare equipment sectors experienced a much sharper decline in investor interest than the healthcare technology and provider segments, the report adds. But there is a […]
Posted in Biotech, Deals, Global, healthcare | Also tagged , , , , | Leave a comment

Activism Is A Bitter Pill More Healthcare Companies May Have To Swallow

by Barbara Ryan In the next three months it is likely that three healthcare companies will face crucial activist votes.  At Alere Inc., Coppersmith Capital Management, LLC wants the company to sell/divest assets which it believes could allow them to pay down over $3B in debt.  In response, Alere is mounting a Hess style defense, […]
Posted in Biotech, Corporate Responsibility, healthcare, leadership, Legal, Strategy | Also tagged , , , , , | Leave a comment

Fixing Biotech's Broken Business Model

Despite some notable successes, the global biotech industry has fallen short of expectations. Strategic collaborations have been on the increase, but there is now a need for more co-operation using new collaboration models, writes Jo Pisani. The current business model on which biotech has relied is flawed. Due to poor rates of return, investment has […]
Posted in Biotech, Deals, Emerging Markets, Europe, Global, Guest Blog, R&D | Also tagged , , , , , , , | Leave a comment
  • Categories

  • Meta